Acumen Pharmaceuticals, Inc.
ABOS
$0.05
Change (1 day)
$5.09
Year High
$1.72
Year Low
Categories
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Earnings for Acumen Pharmaceuticals, Inc. (ABOS)
Earnings in 2023 (TTM): $-52,371,000
According to Acumen Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-52,371,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Acumen Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-52,371,000 | $-52,371,000 |
| 2022 | $-42,856,000 | $-40,475,000 |
| 2021 | $-100,606,000 | $-181,679,000 |
| 2020 | $-7,325,000 | $-7,324,000 |
| 2019 | $-7,907,000 | $-7,862,000 |